We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
-1.72%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$246M
AUM Growth
-$8.32M
Cap. Flow
+$6.35M
Cap. Flow %
2.58%
Top 10 Hldgs %
46.09%
Holding
106
New
14
Increased
20
Reduced
56
Closed
9

Top Buys

Rank Stock Value
1
CTNM
Contineum Therapeutics
CTNM
+$12.9M
2
CVS icon
CVS Health
CVS
+$2.44M
3
BNTX icon
BioNTech
BNTX
+$2.17M
4
EVH icon
Evolent Health
EVH
+$2.15M
5
SYK icon
Stryker
SYK
+$2.12M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$2.67M
2
PODD icon
Insulet
PODD
+$1.94M
3
EYPT icon
EyePoint Inc
EYPT
+$1.91M
4
ATEC icon
Alphatec Holdings
ATEC
+$1.88M
5
LLY icon
Eli Lilly
LLY
+$1.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
76
Jazz Pharmaceuticals
JAZZ
$16.2B
$356K 0.14%
3,334
-560
-14% -$61.6K
SNY icon
77
Sanofi
SNY
$103B
$356K 0.14%
7,330
-5,340
-42% -$258K
ONC
78
BeOne Medicines Ltd
ONC
$33.4B
$349K 0.14%
2,447
-1,245
-34% -$192K
RDY icon
79
Dr. Reddy's Laboratories
RDY
$9.85B
$343K 0.14%
22,500
-5,000
-18% -$71.7K
MDGL icon
80
Madrigal Pharmaceuticals
MDGL
$11.4B
$298K 0.12%
1,065
-66
-6% -$15.7K
VERA icon
81
Vera Therapeutics
VERA
$2.37B
$279K 0.11%
7,718
-37,183
-83% -$1.47M
RCKT icon
82
Rocket Pharmaceuticals
RCKT
$351M
$270K 0.11%
12,530
-2,280
-15% -$52.4K
CRNX icon
83
Crinetics Pharmaceuticals
CRNX
$8.85B
$260K 0.11%
+5,800
New +$268K
EXEL icon
84
Exelixis
EXEL
$14.1B
$258K 0.1%
11,460
-1,680
-13% -$37.3K
RVMD icon
85
Revolution Medicines
RVMD
$40.9B
$256K 0.1%
6,600
-6,310
-49% -$236K
VTRS icon
86
Viatris
VTRS
$20.7B
$239K 0.1%
+22,500
New +$249K
HALO icon
87
Halozyme
HALO
$9.88B
$200K 0.08%
3,815
-1,865
-33% -$81.8K
ARWR icon
88
Arrowhead Research
ARWR
$12.3B
$195K 0.08%
7,522
-160
-2% -$3.93K
SMMT icon
89
Summit Therapeutics
SMMT
$10.7B
$195K 0.08%
25,000
-290,000
-92% -$1.57M
BHVN icon
90
Biohaven
BHVN
$2.08B
$135K 0.06%
+3,900
New +$154K
PTCT icon
91
PTC Therapeutics
PTCT
$6.26B
$131K 0.05%
+4,300
New +$139K
SRRK icon
92
Scholar Rock
SRRK
$5.87B
$125K 0.05%
15,030
-370
-2% -$4.52K
CATX icon
93
Perspective Therapeutics
CATX
$341M
$110K 0.04%
+11,000
New +$159K
LEGN icon
94
Legend Biotech
LEGN
$3.69B
$88.6K 0.04%
2,000
-1,000
-33% -$46.1K
KYTX icon
95
Kyverna Therapeutics
KYTX
$455M
$52.5K 0.02%
7,000
– –
ZLAB icon
96
Zai Lab
ZLAB
$2.06B
$34.7K 0.01%
2,000
– –
GRAL
97
GRAIL Inc
GRAL
$3.05B
$3.69K ﹤0.01%
+240
New +$3.89K
ALT icon
98
Altimmune
ALT
$580M
– –
-92,240
Closed -$939K
ATEC icon
99
Alphatec Holdings
ATEC
$1.49B
– –
-136,000
Closed -$1.88M
CNC icon
100
Centene
CNC
$30.1B
– –
-34,000
Closed -$2.67M
1 2 3
4
5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sectoral Asset Management held 106 positions worth $246M, down 3.3% from $254M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sectoral Asset Management's Q2 2024 filing shows 14 new, 20 increased, 56 reduced and 9 closed positions. Its largest new stake was Contineum Therapeutics: 800,887 shares worth $14.1M. The largest sale was Centene, an estimated $2.67M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sectoral Asset Management's largest Q2 2024 buy was Contineum Therapeutics: 800,887 shares worth $14.1M.
  • Sectoral Asset Management added most to BioNTech in Q2 2024, an estimated $2.17M increase.
  • Sectoral Asset Management's biggest Q2 2024 reduction was Insulet, cutting an estimated $1.94M.
  • Sectoral Asset Management fully exited Centene in Q2 2024, selling an estimated $2.67M.
  • Sectoral Asset Management's ten largest holdings make up 46% of its $246M portfolio in Q2 2024.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q2 2024.
  • Sectoral Asset Management's portfolio value fell 3.3% quarter-over-quarter to $246M.

Based on Sectoral Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.